Abstract
PCSK9 negatively regulates low-density lipoprotein receptor (LDLR) abundance on the cell surface, leading to decreased hepatic clearance of LDL particles and increased levels of plasma cholesterol. We previously identified SURF4 as a cargo receptor that facilitates PCSK9 secretion in HEK293T cells (Emmer et al., 2018). Here, we generated hepatic SURF4-deficient mice (Surf4fl/fl Alb-Cre+) to investigate the physiologic role of SURF4 in vivo. Surf4fl/fl Alb-Cre+ mice exhibited normal viability, gross development, and fertility. Plasma PCSK9 levels were reduced by ∽60% in Surf4fl/fl Alb-Cre+ mice, with a corresponding ∽50% increase in steady state LDLR protein abundance in the liver, consistent with SURF4 functioning as a cargo receptor for PCSK9. Surprisingly, these mice exhibited a marked reduction in plasma cholesterol and triglyceride levels out of proportion to the partial increase in hepatic LDLR abundance. Detailed characterization of lipoprotein metabolism in these mice instead revealed a severe defect in hepatic lipoprotein secretion, consistent with prior reports of SURF4 also promoting the secretion of apolipoprotein B. Despite a small increase in liver mass and lipid content, histologic evaluation revealed no evidence of steatohepatitis or fibrosis in Surf4fl/fl Alb-Cre+ mice. Acute depletion of hepatic SURF4 by CRISPR/Cas9 or liver-targeted siRNA in adult mice confirms these findings. Together, these data support the physiologic significance of SURF4 in the hepatic secretion of PCSK9 and APOB-containing lipoproteins and its potential as a therapeutic target in atherosclerotic cardiovascular diseases.
Introduction
An elevated plasma level of low-density lipoprotein (LDL) is a major risk factor for atherosclerotic cardiovascular disease (Chapman et al., 2011), which is the leading cause of death worldwide. LDL is derived in the circulation by processing of very-low-density lipoprotein (VLDL) particles, which is synthesized and secreted by the liver. In humans, the major protein component of VLDL is APOB100, which is cotranslationally lipidated in the endoplasmic reticulum (ER) (Kolovou et al., 2015). LDL is cleared from circulation by the LDL receptor (LDLR) on cell surfaces. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a soluble protein that is secreted by the liver and negatively regulates LDLR abundance by inducing its degradation (Benjannet et al., 2004).
Proteins destined for extracellular secretion are transported from the endoplasmic reticulum (ER) to Golgi by COPII coated vesicles/tubules (Bonifacino & Glick, 2004; Palade, 1975). SEC24 is a key component of the COPII inner coat, which appears to play a primary role in selecting cargo proteins for export from the ER (Miller et al., 2002). The mammalian genome encodes 4 paralogs of Sec24 (Sec24a-d) (Wendeler et al., 2007). Mice genetically deficient in SEC24A exhibit moderate hypocholesterolemia due to a selective block in PCSK9 secretion from the ER, resulting in an ∽50% reduction in plasma PCSK9 levels (Chen et al., 2013).
We previously reported a whole genome CRISPR screen in HEK293T cells heterologously expressing PCSK9, identifying Surfeit locus protein 4 (SURF4) as the putative cargo receptor potentially linking PCSK9 within the ER lumen to SEC24A on the cytoplasmic face of the ER membrane (Emmer et al., 2018). SURF4 is a 29 kDa protein with multiple transmembrane domains that localize to the ER and ER-Golgi intermediate compartment (ERGIC) (Mitrovic et al., 2008). SURF4 is a homolog of Erv29p, a well-characterized cargo receptor in yeast that mediates the ER to Golgi trafficking of pro-α-mating factor (Belden, 2001). The SURF4 ortholog in C. elegans, SFT-4, controls the ER export of the yolk protein VIT-2 (Saegusa et al., 2018). Recent studies in human cells have also implicated SURF4 in the trafficking of other cargoes, including apolipoprotein B (APOB) (Emmer et al., 2020; Saegusa et al., 2018; B. Wang et al., 2021), erythropoietin (EPO) (Lin et al., 2020), growth hormone, dentin sialophosphoprotein, and amelogenin (Yin et al., 2018). A role for SURF4 in APOB secretion was further supported by a recent study in which acute deletion of hepatic Surf4 in adult mice caused hypocholesterolemia and a reduction in hepatic lipoprotein secretion (X. Wang et al., 2021).
To investigate the physiologic significance of SURF4 in the secretion of PCSK9 and other putative cargoes, we previously generated mice with germline deletion of Surf4, which resulted in early embryonic lethality (Emmer et al., 2020). We now report the generation and characterization of mice with Surf4 selectively inactivated in the liver by combining a conditional Surf4 allele (Surf4fl) with a Cre recombinase expressed under the control of the albumin promoter (Alb-Cre). Surf4fl/fl Alb-Cre+ mice exhibit normal development, survival and fertility, with marked plasma hypocholesterolemia associated with a hepatic secretion defect for PCSK9 and APOB-containing lipoproteins without evidence for liver injury. Acute inactivation of hepatic Surf4 by CRISPR/Cas9 or liver-targeted siRNA in adult mice further confirms these findings and the potential of hepatic SURF4 as a therapeutic target in atherosclerotic cardiovascular disease.
Results
Liver-specific deletion of Surf4 is compatible with normal development and survival in mice
To investigate long term Surf4 inactivation in hepatocytes in vivo, we generated mice with the Surf4 gene genetically inactivated specifically in the liver by combining a previously reported conditional Surf4 allele (in which Surf4 exon 2 is flanked by loxP sites, denoted Surf4fl) (X. Wang et al., 2021) with a Cre recombinase transgene under control of the Albumin promoter (Alb-Cre). Surf4fl/fl Alb-Cre+ mice were observed at the expected Mendelian ratio (Table 1). Both male and female Surf4fl/fl Alb-Cre+ mice were fertile and produce offspring of the predicted genotypes at expected Mendelian ratios (Table 1).
Excision of exon 2 is predicted to result in a frameshift mutation and the generation of a premature termination codon 8 base pairs downstream of the new exon1-3 junction (Fig. 1A). Analysis of genomic DNA collected from mouse tails and livers of Surf4fl/fl Alb-Cre+ mice demonstrated efficient Cre-mediated excision of Surf4 exon 2 only in the liver (Fig. 1B), with the level of exon 2 containing Surf4 transcripts in Surf4fl/fl Alb-Cre+ livers reduced to ∽5% of controls (Fig. 1C). This residual unexcised Surf4 mRNA is likely derived from nonhepatocyte cell types in the liver. Quantitative PCR of liver cDNA using primers outside of exon 2 demonstrated a 38% reduction in total Surf4 mRNA transcript in Surf4fl/fl Alb-Cre+ mice compared to Surf4fl/fl Alb- Cre- littermates, likely due to nonsense mediated mRNA decay (Popp & Maquat, 2013). Analysis of Surf4 mRNA transcripts by RNA sequencing confirmed the expected reduction of reads spanning the exon 1-2 and exon 2-3 junctions in Surf4fl/fl Alb-Cre+ livers compared to controls (150 and 148 versus 2623 and 2490 reads, respectively, Fig. 1D and Fig. S1). Consistent with the qPCR data and incomplete nonsense mediated mRNA decay, we identified 928±51 reads mapping to the exon1-exon3 junction of the Surf4 mRNA in liver from Surf4fl/fl Alb-Cre+ mice and zero in Surf4fl/fl Alb-Cre- samples (Fig. S.1). This residual exon 2 excised mRNA in Surf4fl/fl Alb- Cre+ liver contains a premature stop codon near the start of the SURF4 coding sequence (codon 23 of 270), which is expected to be translated into a nonfunctional, truncated protein (Fig. 1A).
We also detected 404±39 reads (none in controls) mapping to the exon1-4 junction of an alternatively spliced Surf4 mRNA in Surf4fl/fl Alb-Cre+ samples (Fig. 1D). Exclusion of exon 2 and 3 is predicted to restore the reading frame and result in the production of an internally deleted SURF4, missing ∽1/3 of the full length sequence (Fig. 1A). Though also likely to be nonfunctional, residual activity and/or a dominant-negative effect of this internally deleted SURF4 cannot be excluded.
Reduced circulating PCSK9 and increased LDLR levels in Surf4fl/flAlb-Cre+ mice
We previously demonstrated a key role of SURF4 in the efficient trafficking of PCSK9 heterologously expressed in HEK293T cells (Emmer et al., 2018). To test the dependence of PCSK9 secretion on SURF4 in vivo, we first examined steady state serum PCSK9 levels in Surf4fl/fl Alb-Cre+ and Surf4fl/fl Alb-Cre- control mice. Serum PCSK9 levels were reduced by ∽60% in Surf4fl/fl Alb-Cre+ compared to Surf4fl/fl Alb-Cre- mice (from 46.0±19.0 ng/mL to 17.8±6.42 ng/mL, Fig. 2A), though PCSK9 accumulation was not observed in liver lysates (Fig. 2B-C). Quantitative RT-PCR revealed that Pcsk9 mRNA levels were also unchanged (Fig. S.2), consistent with a defect in PCSK9 protein secretion rather than gene expression as the cause for decreased plasma PCSK9 levels.
In contrast to the above findings, Wang et al reported no change in plasma PCSK9 levels in Surf4fl/fl Alb-Cre+ mice (B. Wang et al., 2021). To address this issue, and to exclude complex adaptation to hepatic SURF4 deletion induced in utero, we acutely inactivated hepatic Surf4 in adult mice using a previously reported Cas9 mouse system (X. Wang et al., 2021). Analyses utilizing 3 different Surf4 targeting sgRNAs demonstrated a reproducible ∽40% reduction in plasma PCSK9 levels for all mice receiving Surf4 targeting sgRNA compared to control mice (Fig. 2D), consistent with our findings in Surf4fl/fl Alb-Cre+ mice.
Since PCSK9 is a negative regulator of LDLR, we next quantified LDLR levels in liver lysates collected from control and Surf4fl/fl Alb-Cre+ mice. As shown in Fig. 2E-F, Surf4fl/fl Alb-Cre+ mice exhibit an ∽1.5-fold increase in LDLR abundance in liver lysates compared to controls, consistent with the observed ∽60% reduction in circulating PCSK9 level.
Marked reduction of plasma cholesterol in Surf4fl/flAlb-Cre+ mice
Humans with heterozygous loss of function mutations in PCSK9 exhibit an ∽40% reduction in circulating cholesterol (Cohen et al., 2005) with a similar reduction observed in Pcsk9+/- mice (Rashid et al., 2005). Though Surf4fl/fl Alb-Cre+ mice exhibit similar reductions in PCSK9, total serum cholesterol is markedly reduced (from 54.3±15.1 mg/dL in Surf4fl/fl Alb-Cre- mice to 9.51±2.6 mg/dL in Surf4fl/fl Alb-Cre+ mice) (Fig. 2G). No change in cholesterol was observed in the limited numbers of mice haploinsufficient for Surf4 in the liver (Surf4fl+l Alb-Cre+). Analysis of fractionated pooled sera demonstrated marked reductions in cholesterol and triglyceride content in Surf4fl/fl Alb-Cre+ mice among all 3 major classes of lipoproteins – very low density lipoprotein (VLDL), low density lipoprotein (LDL), and high density lipoprotein (HDL) (Fig. 2H). This striking hypocholesterolemia phenotype is sustained through at least 1 year of age (Fig. S.3B), with no difference in body mass between Surf4fl/fl Alb-Cre- and Surf4fl/fl Alb-Cre+ littermates (Fig. S.3A and S.3C).
Consistent with a role of SURF4 in the ER export of APOB-containing lipoproteins (X. Wang et al., 2021), the mean serum APOB level in fasted Surf4fl/fl Alb-Cre+ mice was 3.88±2.63 mg/mL, a >98% reduction compared to Surf4fl/fl Alb-Cre- mice (300±157mg/mL, Fig. 3A). Western blotting demonstrated a trend towards an accumulation of APOB in the livers of Surf4fl/fl Alb-Cre+ mice compared to littermate controls, predominantly in an endoglycosidase H (endo H) sensitive form (Fig. 3B-C), indicative of ER retention (Freeze & Kranz, 2010).
We next examined hepatic triglyceride secretion in Surf4fl/fl Alb-Cre+ and control mice. For this experiment, mice were fasted to remove intestinal absorption of dietary fat and tissue lipid uptake was blocked by administration of a lipoprotein lipase inhibitor, with liver triglyceride output subsequently monitored by sampling of plasma triglycerides over 24 hours. Following fasting and inhibition of triglyceride hydrolysis, blood glucose levels fell equivalently between Surf4fl/fl Alb-Cre+ and Surf4fl/fl Alb-Cre- littermates (Fig. 3D). Although serum cholesterol and triglyceride levels steadily increased in both groups over time, both levels were consistently and significantly lower in Surf4fl/fl Alb-Cre+ mice compared to littermate controls (Fig. 3E-F).
Following an initial decrease in the first hour after lipoprotein lipase inhibition, serum APOB levels steadily rose in control mice (Fig. 3G). In contrast, serum APOB levels were markedly reduced at baseline in Surf4fl/fl Alb-Cre+ mice, and showed minimal increase after lipoprotein lipase inhibition.
Intestinal lipid absorption and tissue lipid uptake are unaffected in Surf4fl/flAlb-Cre+ mice
To assess the potential role of hepatic Surf4 gene expression on dietary lipid absorption, mice were fed a 3H triolein-labelled lipid load following an overnight fast. No significant differences in blood glucose, serum triglycerides, non-esterified fatty acids, or total intestinal uptake of dietary lipids were observed between control and Surf4fl/fl Alb-Cre+ mice (Fig. 4A-D). Similarly, no significant differences were observed in tissue lipid uptake or fatty acid oxidation between Surf4fl/fl Alb-Cre+ mice and littermate controls (Fig. 4E-F).
Loss of liver Surf4 expression results in mild lipid accumulation but no steatohepatitis or fibrosis
Surf4fl/fl Alb-Cre+ mice exhibited mildly enlarged livers (Fig. 5A), with a small increase in hepatic fat content and a reduction in lean mass compared to littermate controls (Fig. 5B). However, no differences were observed in fasting hepatic cholesterol, triglyceride, phospholipid, or nonesterified fatty acid content (Fig. 5C). Hepatic lipid accumulation can lead to steatohepatitis and liver damage (Ipsen et al., 2018). However, at 8-12 week of age, serum albumin, bilirubin, and liver function markers were indistinguishable between Surf4fl/fl Alb-Cre+ and control mice (Fig. S.4 and Fig. 5D) and histologic analyses detected no evidence for steatohepatitis or fibrosis (Fig. 5E). Finally, deep sequencing of liver mRNA identified only limited gene expression changes in response to Surf4 deletion (Fig. 5F). Significant downregulation was observed for several genes involved in fatty acid biosynthesis processes (Fig. 5H). The most significantly upregulated gene in Surf4fl/fl Alb-Cre+ liver was Derl3, a component of the ERAD pathway, which could be induced by protein accumulation in the ER of Surf4fl/fl Alb-Cre+ mice. Genes involved in the unfolded protein response, such as Ire1, Aft6, and Perk (Hetz et al., 2020), were not upgregulated in Surf4fl/fl Alb-Cre+ mice (Fig. 5F).
Dose-dependent reduction of plasma lipids in response to depletion of SURF4 by siRNA
To confirm the profound hypocholesterolemia with few adverse consequences observed in Surf4fl/fl Alb-Cre+ mice, and to further explore SURF4 inhibition as a potential therapeutic approach, we next tested depletion of hepatic SURF4 using liver-targeted siRNA in adult mice. Mice were treated with control or Surf4 targeting siRNA at multiple doses between 0.5-4 mg/kg. Mice treated with Surf4 targeting siRNA demonstrated a dose-dependent reduction of liver Surf4 mRNA and protein levels (Fig. 6A and Fig. S.4). As expected, plasma PCSK9, cholesterol, triglycerides, APOB, and APOA1 levels were inversely correlated with siRNA dosage, with the highest siRNA dose (4 mg/kg) resulting in cholesterol levels similar to those observed in Surf4fl/fl Alb-Cre+ mice (Fig. 6B-D and Fig. S4). Finally, no differences in plasma ALT and AST levels were observed between control and siRNA treated mice, suggesting that siRNA treatment and Surf4 depletion does not lead to liver injury, even at the highest siRNA dose (Fig. 6E-F).
Discussion
We found that embryonic deletion of Surf4 in hepatocytes results in profound hypocholesterolemia in mice associated with impaired hepatic lipoprotein secretion and normal dietary fat absorption. In addition, we also demonstrated that plasma PCSK9 levels are reduced in Surf4fl/fl Alb-Cre+ mice. Hepatocyte specific Surf4 deletion was well tolerated, with only modest increases in hepatic mass and lipid content, and no evidence of hepatic dysfunction or steatohepatitis. Finally, we confirm these findings by siRNA depletion of hepatic SURF4 in adult mice, which leads to reductions of plasma cholesterol, triglycerides, and PCSK9 in a dose dependent manner without apparent deleterious consequences in the liver.
We previously reported that PCSK9 is dependent on SURF4 for efficient secretion in cultured HEK293T cells (Emmer et al., 2018). In contrast, Shen et al reported that depletion of SURF4 by siRNA in cultured human hepatocytes leads to increased Pcsk9 gene expression resulting in increased rather than decreased PCSK9 secretion (Shen et al., 2020). The same group also recently reported analysis of Surf4fl/fl Alb-Cre+ mice, observing no change in plasma PCSK9 levels, in contrast to our findings in a similar genetic model. Our current findings, using three independent mouse models, are consistent with our previous in vitro data and support a physiologic role for SURF4 in facilitating the efficient transport of PCSK9 (as well as APOB) through the secretory pathway. The decrease in plasma PCSK9 in Surf4fl/fl Alb-Cre+ mice is similar to that observed in SEC24A-deficient mice (Chen et al., 2013). Additionally, we also detected a 1.5 fold increase in LDLR level in liver lysates collected from Surf4fl/fl Alb-Cre+ mice, consistent with the reduction in circulating PCSK9. The increased hepatocyte LDLR levels in Surf4fl/fl Alb-Cre+ mice are not accompanied by upregulation of Ldlr mRNA as measured by RNA-seq analysis, consistent with the increase in LDLR abundance being mediated by PCSK9 activity rather than an increase in gene expression. Furthermore, a recent report by Gomez- Navarro et al independently demonstrated that PCSK9 relies on both SEC24A and SURF4 for secretion and that chemical disruption of SEC24A-SURF4 interaction is sufficient to reduce PCSK9 secretion (Gomez-Navarro et al., 2022). Taken together, these data are consistent with the proposed function of SURF4 as a cargo receptor linking PCSK9 in the ER lumen to the SEC24A component of the COPII coat on the cytoplasmic face of the ER (Emmer et al., 2018). The basis for the discrepancy between our findings and those of B. Wang and colleagues (B. Wang et al., 2021) is unclear but may be related to differences in mouse genetic or husbandry (Tang et al., 2017), or to technical differences in PCSK9 quantification.
The profound hypocholesterolemia we observed in Surf4fl/fl Alb-Cre+ mice is in agreement with two other studies in which hepatic Surf4 was acutely inactivated using an AAV/Cas9 mouse system (X. Wang et al., 2021) or a similar Surf4fl/fl and Alb-Cre model (B. Wang et al., 2021). We also confirmed this observation in a third model using siRNA mediated knockdown of Surf4 transcripts in mouse livers. The decrease in circulating cholesterol is likely due to impaired secretion of APOB containing lipoprotein particles from the liver, and is consistent with multiple previous reports suggesting that APOB is a cargo for SURF4 (Emmer et al., 2020; Saegusa et al., 2018; B. Wang et al., 2021; X. Wang et al., 2021). Despite remarkably low plasma cholesterol levels, Surf4fl/fl Alb-Cre+ mice exhibit normal growth and fertility compared to littermate controls. Plasma cholesterol is an important precursor for steroid hormone synthesis. However, given that both male and female Surf4fl/fl Alb-Cre+ mice are fertile, it is unlikely that sex hormone synthesis is significantly perturbed in these mice. Consistent with this conclusion, Chang et al recently reported that even though lipid droplets and cholesterol are depleted in the adrenal glands of Surf4fl/fl Alb-Cre+ mice, circulating adrenal steroid hormone levels are unchanged under resting and stressed conditions (Chang et al., 2021).
Impaired protein secretion could lead to accumulation of proteins in the ER lumen, potentially triggering activation of UPR pathways and induction of ERAD. Indeed, livers from Surf4fl/fl Alb- Cre+ mice exhibited upregulation of mRNA for Derl3, an ER transmembrane protein that is a functional component of the ER-associated degradation (ERAD) complex (Oda et al., 2006). While Derl3 is thought to be a target of the IRE1-XBP1 pathway, we did not detect upregulation of Ire1 or Xbp1, or other ERAD components at the mRNA levels in Surf4fl/fl Alb-Cre+ mice. Instead upregulation of Derl3 could be an adaptive response to the protein accumulation in the ER leading to the rapid degradation of these proteins. This can also explain the lack of liver PCSK9 accumulation and a mild increase in liver APOB levels (relative to a significant reduction of plasma levels) in Surf4fl/fl Alb-Cre+ mice.
Recently, Musunuru et al reported that in vivo CRISPR-mediated base editing of hepatic PCSK9 leads to an ∽60% reduction in plasma cholesterol in cynomolgus monkeys without overt hepatotoxicity (Musunuru et al., 2021). Our data suggest that hepatic Surf4 could be similarly targeted, potentially achieving an even more profound reduction in plasma cholesterol without deleterious consequences. Indeed, it has been shown that inactivation of hepatic Surf4 is protective against diet-induced atherosclerosis in mice with PCSK9 overexpression (X. Wang et al., 2021), LDLR deficiency (B. Wang et al., 2021), and APOE deficiency (Shen et al., 2022).
Furthermore, polymorphism and mild reduction of SURF4 expression strongly associate with lower plasma lipid levels and reduced risks of cardiovascular disease in human populations (X. Wang et al., 2021). Here, we further demonstrate that even more modest reductions in SURF4 induced by siRNA targeting are likely to confer significant lipid-lowering, though such benefits must be weighed against potential toxicity from disrupting the secretion of other SURF4- dependent cargoes.
Materials and Methods
Animal care and use
All animal care and use complied with the Principles of Laboratory and Animal Care established by the National Society for Medical Research. All animal protocols in this study have been approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Michigan (protocol number PRO00009304) and the IACUC of Peking University. Both male and female mice were used in this study unless otherwise specified.
Generation of conditional Surf4 knockout mice
The generation of mice carrying a conditional Surf4 allele in which exon 2 of the gene is flanked by 2 loxP sites (Surf4fl) has been previously described (X. Wang et al., 2021). Surf4fl/+ mice were crossed with mice carrying an Alb-Cre transgene (Adams et al., 2014) to obtain Surf4fl/+ Alb-Cre+ mice. These mice were then crossed to Surf4fl/fl mice to generate Surf4fl/fl Alb-Cre+ mice. The Surf4fl and Alb-Cre alleles were maintained on the C57BL/6J background by continuous backcrosses to C57BL/6J mice (0006640, Jackson Laboratory, Bar Harbor ME).
Genotyping assays
Tail clips were obtained from 2 weeks old mice for genomic DNA isolation and genotyping. PCR was performed using Go-Taq Green Master Mix (Promega, Madison, WI) and resulting products were resolved by 3% agarose gel electrophoresis. All primers used for genotyping are listed in Table S.1. Those used for genotyping the Surf4 locus are also depicted in Fig. 1A. For the Alb- Cre transgene, parental mice were genotyped using promoter-specific Cre primers and offspring were genotyped with primers that detect the Cre transgene (Table S.1).
Blood and tissue collection
Mice were fasted overnight for up to 16 hours prior to sample collection. For non-terminal experiments, blood was collected from the superficial temporal vein using a 4 mm sterile lancet. For terminal experiments, mice were first euthanized by isoflurane inhalation and blood was drawn from the inferior vena cava using a 23G needle and a 1 ml syringe. Blood was collected into a serum separator tube (365967, BD, Franklin Lakes NJ), allowed to clot at room temperature for at least 10 minutes, and centrifuged at 15,000 g for 10 minutes to separate serum. Sera were aliquoted and stored at -80°C. Liver tissue were collected as previously described (Emmer et al., 2020).
Analysis for sera from Surf4 liver knockout mice
Sera were analyzed by a colorimetric assay for total cholesterol (SB-1010-225, Fisher Scientific, Hampton NH) and by ELISAs for PCSK9 (MPC900, R&D Systems, Minneapolis MN) and APOB (ab230932, Abcam, Cambridge UK). Serum lipoprotein fractionation assays were performed at the University of Cincinnati Mouse Metabolic Phenotyping Center. Sera were pooled from 5 mice for each genotype and fractionated by fast liquid protein chromatography (FPLC) into 50 fractions. Cholesterol (NC9343696, Fisher, Hampton NH) and triglyceride (TR213, Randox Laboratories, Crumlin UK) content in each fraction were determined using a microliter plate enzyme-based assay. Liver function tests were performed at the University of Michigan In-Vivo Animal Core (IVAC) with sera collected from individual mice using a Liasys analyzer (AMS Alliance).
Hepatic lipoprotein secretion assay
Hepatic triglyceride secretion assays were performed at the University of Michigan Mouse Metabolic Phenotyping Center as previously described (Millar et al., 2005). Blood levels of glucose were measured using a glucometer (Acucheck, Roche, Basel Switzerland) and plasma levels of cholesterol (SB-1010-225, Fisher Scientific, Hampton NH) and triglycerides (10010303, Cayman Chemical, Ann Arbor MI) were determined using colorimetric assay kits. Plasma APOB levels were determined by ELISA (ab230932, Abcam, Cambridge UK).
Oral fat tolerance test and lipid flux assay
Oral fat tolerance test and lipid flux assay were performed at the University of Michigan Mouse Metabolic Phenotyping Center. Mice were fasted overnight and 3H triolein-labeled olive oil (0.026 μCi/μl) was given via oral gavage at 5 μl/g of body mass. Blood samples were collected at time 0, 30, 60, 120, and 240 minutes after the gavage via tail vein bleeding. Plasma levels of triglyceride (10010303, Cayman Chemical, Ann Arbor MI) and non-esterified fatty acid (NEFA- HR (H2), Wako Pure Chemical Industries, Ltd, Richmond VA) were determined using the colorimetric assays. Plasma radioactivity, reported as 3H disintegration per minute (dpm), were determined from 2 μl of serum at each time point.
Tissues samples (liver, heart, gastrocnemius muscle, and perigonadal fat) were collected at the 240 minute time point, flash frozen in liquid nitrogen and stored at -80ºC. For the liver, tissue composition was measured using an NMR-based analyzer (EchoMRI™) immediately upon harvest and prior to freezing. 3H-triolein flux was estimated as previously described (Kusminski et al., 2012; Ye et al., 2014).
Liver lipid extraction and quantification
Liver lipid extraction and quantification were performed at the University of Cincinnati Mouse Metabolic Phenotyping Center. Lipids were extracted using the Folch’s extraction method as previously described (Folch et al., 1957). Levels of cholesterol, triglycerides, free fatty acids, and phospholipids in each sample were quantified using specific colorimetric assays.
Immunoblotting
Lysates were prepared from snap frozen liver tissues and resolved on a 4-20% Tris-glycine gel as previously described (Emmer et al., 2020). Immunoblots were probed with antibodies against APOB (70R-15771, 1:1000, Fitzgerald Industries International, Acton MA), PCSK9 (ab31762, 1:1000, Abcam, Cambridge UK), LDLR (ab52818, 1:1000, Abcam, Cambridge UK), HSP90 (4877, 1:1000, Cell Signaling Technology, Danvers MA), and GAPDH (ab181602, 1:5000, Abcam, Cambridge UK). For endoglycosidase H assays, 30 μg of lysate was analyzed as previously described using the above antibodies (Emmer et al., 2018).
Histology
Tissue processing, embedding, sectioning, hematoxylin and eosin (H&E), and picrosirius red staining were performed at the University of Michigan In-Vivo Animal Core (IVAC). Slides were reviewed by an investigator blinded to the genotype.
Analysis of liver mRNA
Liver RNA was isolated from tissue using an RNeasy Plus Mini Kit according to the manufacturer’s instructions (74134, Qiagen, Hilden Germany) and reverse transcription was performed using oligo(dT)12-18 primers (18418012, Invitrogen, Waltham MA). Quantitative PCR reactions were performed using Power SYBR Green PCR Master Mix (4367659, Invitrogen, Waltham MA) and primers listed in Table S.1. Total Surf4 mRNA abundance was calculated using data from primers that bind to exon 5 and 6 on the Surf4 transcript. Abundance of Surf4 mRNA that contains exon 2 was obtained using primers specific to exon 2 and exon 3 of the transcript. Normalized transcript abundance was calculated by the 2-ΔΔCt method using Gapdh and Rpl37 as housekeeping controls.
Library preparation and next generation sequencing was performed at the University of Michigan Advanced Genomics Core. Demultiplexed fastq files were aligned against the mouse reference genome (GRCm38.92) using STAR (Dobin et al., 2013) and quantified with RSEM (Li & Dewey, 2011). Differential expression analysis was performed by DESeq2 (Love et al., 2014). Sequencing coverage for the Surf4 transcript was analyzed using the ggsashimi package (Garrido-Martn et al., 2018).
Acute inactivation of hepatic Surf4 in adult mice
Hepatic Surf4 was selectively inactivated in adult mice by injection of adeno-associated virus (AAV) delivering a hepatocyte-specific Cre and a guide RNA targeting Surf4 or LacZ (control) into a Cre-dependent spCas9 knockin mice (Platt et al., 2014) as previously described (X. Wang et al., 2021). Blood samples were collected as previously described (X. Wang et al., 2021) and plasma PCSK9 concentrations were measured by the commercial kit (CY-8078 of MBL) according to the manufacturer’s protocol.
To deplete Surf4 mRNA, N-acetylgalactosamine (GalNAc) conjugated siRNA oligos are synthesized to ensure liver targeting. SiRNA targeting murine Surf4 or GalNAc conjugated siRNA with scrambled sequence (siCTL) were injected into 6 weeks old male mice subcutaneously with concentrations indicated in the figures. Seven days after injection, blood samples were collected by tail vein, and then centrifuged at 6000 rpm, 4°C for 10 min to harvest plasma. The plasma PCSK9 concentrations were measured by the commercial kit (CY-8078 of MBL) according to the manufacturer’s protocol. SiRNA sequences are listed in Table S.2.
Competing interests
None
Acknowledgements
This work was supported by NIH grants R35HL135793 (DG), R01HL148333 (RK), R01HL157062 (RK), and K08HL148552 (BTE); the National Key R&D Program grant 2018YFA0506900 (XWC); the National Science Foundation of China grants 91957119, 91954001, 31571213, and 31521062 (XWC); the American Heart Association Predoctoral Fellowship 20PRE35210706 (VTT); the University of Michigan Rackham Predoctoral Fellowship (VTT). DG is a Howard Hughes Medical Institute Investigator.